Novartis said its RNA therapy del-brax met goals of a Phase 1/2 study in facioscapulohumeral muscular dystrophy (FSHD), an inherited muscle disorder that currently has no FDA-approved medicines. Del-brax is one of three RNA therapies from Novartis’s $12 billion acquisition of Avidity Biosciences.
The post Novartis RNA Med From $12B Deal Keeps Building Case to Become First Therapy for Rare Muscle Disease appeared first on MedCity News.
